Industry Workshops

Industry Workshops provide an opportunity for AMCP corporate members to showcase their latest drug therapies, technologies, and a wealth of products and services affecting professionals working in managed care pharmacy.

All Industry Workshops take place on Tuesday, Oct. 19, from 11:30am–12:30pm.

Materials presented in workshops may be promotional and concentrate on a specific product, service, or therapeutic area. Therefore, these presentations are considered promotional and do not offer continuing education credit.

Industry Workshops with a PIE logo include preapproval information exchange information. Subject to federal laws and regulations, attendance at these sessions is restricted to payors, formulary committee, or other similar entity representatives with knowledge and expertise in health care economic analysis, carrying out responsibilities for the selection of drugs for coverage or reimbursement. Look for additional details on the AMCP PIE Information page.

Tuesday, October 19, 11:30am-12:300pm

Bimekizumab: An IL-17 A and IL-17 F Inhibitor
Room: Summit 8/9

PIE Description: In this workshop, an investigational humanized monoclonal IgG1 antibody for the management of adult patients with moderate-to-severe plaque psoriasis will be reviewed. The session will begin with an overview of the investigational product, bimekizumab and its novel mechanism of action as an IL-17A and IL-17F inhibitor, followed by a review of the key clinical attributes relevant to the management of plaque psoriasis. Finally, the results of bimekizumab’s phase 3 pivotal studies, including study design, key clinical endpoints, and adverse event profile will be presented.

Speaker(s): Eddie Lee, PharmD. Head of HEOR Strategy, UCB, Inc.
Tae Oh, PharmD, Medical Solutions Lead Dermatology, UCB, Inc.

Sponsored by UCB, Inc.

 

Industry Workshop sponsorship opportunities are available for AMCP Corporate Members in good standing. Contact Laura Larson, assistant director, national meeting sales, at llarson@amcp.org for more details.